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Abstract
Tumor xenografts in immunodeficient mice, while routinely used in cancer research, preclude studying interactions of
immune and cancer cells or, if humanized by allogeneic immune cells, are of limited use for tumor-immunological
questions. Here, we explore a novel way to generate cancer models with an autologous humanized immune system. We
demonstrate that hematopoietic stem and progenitor cells (HSPCs) from bone marrow aspirates of non-metastasized
carcinoma patients, which are taken at specialized centers for diagnostic purposes, can be used to generate a human
immune system in NOD-scid IL2rc(null) (NSG) and HLA-I expressing NSG mice (NSG-HLA-A2/HHD) comprising both,
lymphoid and myeloid cell lineages. Using NSG-HLA-A2/HHD mice, we show that responsive and self-tolerant human T cells
develop and human antigen presenting cells can activate human T cells. As critical factors we identified the low potential of
bone marrow HSPCs to engraft, generally low HSPC numbers in patient-derived bone marrow samples, cryopreservation
and routes of cell administration. We provide here an optimized protocol that uses a minimum number of HSPCs, preselects
high-quality bone marrow samples defined by the number of initially isolated leukocytes and intra-femoral or intra-venous
injection. In conclusion, the use of diagnostic bone marrow aspirates from non-metastasized carcinoma patients for the
immunological humanization of immunodeficient mice is feasible and opens the chance for individualized analyses of anti-
tumoral T cell responses.
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Introduction
The immunobiology of solid tumors is mostly studied in small
animal models, primarily in mice. These studies are mainly based
on tissue- or cell-specific expression of oncogenes, chemical-
induced carcinogenesis or spontaneously arising tumors in
immunocompetent mice [1]. In addition, immunodeficient mice
are used to establish xenografts of human tumors, but these models
suffer from either the complete absence of human immune cells or
poor engraftment of certain hematopoietic lineages after hemato-
poietic stem and progenitor cell (HSPC) transplantation. Some
authors therefore used the transfer of autologous mature
peripheral blood mononuclear cells or T cells into tumor-
xenograft bearing mice, but xenoreactivity of the transferred cells
limits the experimental options [2–4].
The development of immunodeficient mice lacking the IL-2
receptor-c chain (e.g. NOD-scid IL2rc(null)) in the beginning of
the 2000s led to a breakthrough as these new mouse strains enable
an increased engraftment frequency of primary human tumor cells
[5] and efficient engraftment of HSPCs with subsequent develop-
ment of myeloid and lymphoid immune cells (reviewed in [6]).
Simultaneous transplantation of tumor cell lines with cord-blood
derived HSPCs [7] demonstrated that both cell types could
successfully co-engraft. However, the impact of allograft responses
against the tumor cells is unknown and consequently the
experimental results may be difficult to interpret in this system.
Furthermore, anti-tumoral T cell responses can’t be analyzed due
to the HLA-mismatch between the tumor and human immune
cells. Therefore, transplantation of syngeneic immune and cancer
cells would be needed.
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This may be achieved by transplantations of autologous HSPCs
from peripheral blood after stem cell mobilization. Studies on
healthy donors have shown long-term engraftment in immunode-
ficient mice [8–10]. However, hematopoietic stem cell mobiliza-
tion of non-metastasized carcinoma patients for research purposes
is ethically questionable. Alternatively, HSPCs from carcinoma
patients may be isolated from bone marrow (BM) aspirates, which
are taken in specialized clinical centers for the detection of
disseminated cancer cells (DCCs) following standardized diagnos-
tic procedures [11]. Furthermore, bone marrow aspiration, when
performed under aseptic conditions during general anaesthesia, is
currently the preferred method to obtain hematopoietic stem cells
with regard to invasiveness and morbidity. This prompted us to
explore the suitability of diagnostic bone marrow aspirates from
non-metastasized carcinoma patients for the generation of a
patient-matched immune system in immunodeficient mice,
providing a basis for preclinical tumor-immunological studies.
Materials and Methods
Ethics Statement
Bone marrow was aspirated from 77 unselected breast, lung,
prostate or oesophageal cancer patients with no evidence of
metastasis at the time of surgery and according to the standards of
the International Union Against Cancer (UICC). Informed written
consent was obtained according to guidelines approved by the
local ethics committee (Ethics committee of the Medical Faculty of
the University of Regensburg, ethics vote number 07/79).
Umbilical cord-blood was obtained from healthy, full-term
pregnancies with informed written consent of the parents
according to guidelines approved by the local ethics committee
(Ethics committee of the Medical Faculty of the University of
Regensburg, ethics vote numbers 12-101-0038 and 08/021).
Peripheral mononuclear cells were isolated from adult, healthy
volunteers with informed written consent according to guidelines
approved by the local ethics committee (Ethics committee of the
Medical Faculty of the University of Regensburg, ethics vote
number 12-101-0038.) All approved experimental animal proce-
dures were conducted to german federal and state regulations
(Regierung Oberpfalz, 54-2531.1-01/08. -17/11 and -28/11).
Mice
NOD.Cg-Prkdcscid IL2rgtmWjl/Sz (also termed NSG) and
NOD.Cg-Prkdcscid Il2rgtm1Wjl Tg(HLA-A/H2-D/B2M)1Dvs/SzJ
(also termed NSG-HLA-A2/HHD) mice were purchased from the
Jackson Laboratory USA and maintained under specific-pathogen
free conditions, with acidified water and food ad libitum in the
research animal facilities of the University of Regensburg,
Germany. C57BL/6 mice were derived from in-house breedings.
All approved experimental animal procedures were conducted to
german federal and state regulations (Regierung Oberpfalz, 54-
2531.1-01/08. -17/11 and -28/11).
Human Cell Preparation
Mononuclear cells from human bone marrow, cord-blood and
peripheral blood samples were obtained by density centrifugation
on 60% Percoll (GE Healthcare, Munich, Germany), stored in
RPMI 1640 o/n at 4uC, cryoconserved or immediately subjected
to the isolation of CD34+ HSPCs. CD34+ HSPCs cells were
isolated by positive magnetic selection using the CD34-Mi-
crobead-Kit (Miltenyi-Biotech, Bergisch-Gladbach, Germany).
Purity of CD34+ cells was .90%. Mononuclear cells from bone
marrow were cryoconserved in medium with 10% DMSO, 5%
FBS, 12.5% Dextran-40 (AlleMan Pharma, Pfullingen, Germany)
and 2.5% ACD-A (Sigma-Aldrich, Taufkirchen, Germany) and
frozen with 1uC/min at 280uC in a cryo-freezing container
(Nalgene Mr. Frosty, Sigma-Aldrich, Taufkirchen, Germany).
After o/n storage at 280uC, cells were transferred to liquid
nitrogen. Cells were thawed for 3 min in the waterbath at 37uC,
an equal volume of medium with 2.5% BSA (Sigma-Aldrich,
Taufkirchen, Germany) was added and after 10 min cells were
washed with 10 ml medium plus 1.25% BSA at 300 g, 4uC for
10 min.
Generation of Humanized Mice
Neonatal NSG mice were irradiated 24–48 h after birth with
1 Gy, adult NSG or NSG-HLA-A2/HHD mice with 3 Gy and
mice were transplanted 3–5 hours later either intra-hepatically
(i.h.), intra-venously (i.v.) or intra-femorally (i.f.) with CD34+
HSPCs. Mice were irradiated with a linear accelerator (Primus,
Siemens Healthcare, Germany, 6 MV photon-emission with
2 Gy/min). Intra-hepatic injections were done with an insulin
syringe (Microfine, 29G, U-50, BD Biosciences, Heidelberg,
Germany) in a volume of 30 ml with up to 16105 CD34+ cells.
For intra-femoral applications the right femur was punctured and
up to 36105 CD34+ cells in a volume of 20 ml were injected with
an insulin syringe (Microfine, 29G, U-50, BD Biosciences,
Heidelberg, Germany). Mice were anesthetized i.p. for intra-
femoral injections with midazolam 5 mg/kg body weight (BW),
fentanyl 0.05 mg/kg BW, medetomidin 0.5 mg/kg BW. Anesthe-
sia was antagonized with flumazenil 0.5 mg/kg BW, atipamezol
2.5 mg/kg BW, naloxon 1.2 mg/kg BW). Buprenorphin (0.1 mg/
kg KG, s.c.) was injected as an analgesic. Intra-venous injections
were performed into the lateral tail vain with an insulin syringe
(Microfine, 29G, U-50, BD Biosciences, Heidelberg, Germany)
and a volume of 200 ml with up to 4.66105 CD34+ cells.
Morbidity associated with irradiation of 3 Gy was observed in
4,3% in NSG and in 6.5% of NSG-HLA-A2/HHD mice.
Flow Cytometry
To validate the purity of the separated CD34+ cells, flow
cytometric analyses were performed. Separated CD34+ cells were
stained with FITC-conjugated anti-human hematopoietic lineage
cocktail (ebioscience, Frankfurt, Germany) and PE-conjugated
anti-CD34 (581, Biolegend, London, UK) for 20 min at 4uC.
Afterwards cells were washed with PBS/2% FCS/0.01%NaN3
and fixed with 1% formaldehyde.
Levels of human hematopoietic cells in transplanted mice were
assessed by multicolor flow cytometry. At defined time points,
50 ml of peripheral blood was drawn into EDTA-coated tubes and
stained for flow cytometric analysis as described below. Also, at 18
to more than 20 weeks after transplantation of CD34+ HSPCs,
spleen and bone marrow of humanized mice were removed. Single
cell suspensions from bone marrow were prepared by flushing
femora and tibiae. Single cell suspensions from spleen were
prepared by gently grinding the organs between two layers of a
41 mm THOMAPOR strainer (Reichelt Chemie, Heidelberg,
Germany). Except for peripheral blood samples of reconstituted
mice, single cell suspensions of the organs were stained with
viability dye eFlour 780 (ebioscience, Frankfurkt, Germany) for
live/dead cell discrimination, To reduce non-specific binding
single cell suspensions were incubated for 10 min at 4uC with anti-
mouse CD16 (2.4G2, own production) and PBS/10% AB-serum
(Bio-Rad, Munich, Germany) and subsequently stained with
fluorescence-labeled antibodies for 30 min at 4uC. After lysis of
erythrocytes for 10 minutes at room temperature with BD lysis
solution (BD Bioscience, Heidelberg, Germany), samples were
washed two times with PBS/2% FCS/0.01% NaN3. Cells were
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analyzed on a LSR II machine equipped with FACS DIVA 5.03
software (BD Bioscience, Heidelberg, Germany) and data was
analyzed with FloJo 8.8.6 (Treestar, Ashland, USA). The cells
were stained using the following antibodies purchased from
Biolegend (London, United Kingdom): anti-human CD3-FITC
(HIT3a), anti-human CD3-PerCP-Cy5.5 (SK7), anti-human CD4-
PE (OKT4), anti-human CD8-Alexa Flour 700 (HIT8a), anti-
human CD10-PE (MEM-78), anti-human CD19-PE (HIB19),
anti-human CD33-PerCP-Cy5.5 (WM53), anti-human CD38-
FITC (HIT2), anti-human CD45-Alexa Flour 700 (HI30), anti-
human CD45-APC (HI30), anti-human CD45RA-Brilliant Violett
510 (HI100), anti-human CD27-Brilliant Violett 421 (O323), anti-
human IgD-PerCP-Cy5.5 (IA6-2), anti-human IgM-Pacific Blue
(MHM-88). The rat anti-mouse CD45-APC (30-F11) antibody
was purchased from ebioscience (Frankfurt, Germany).
Mixed Lymphocyte Reactions
Single cell suspensions from spleen and bone marrow of 2–3
mice derived from the same HSPC-donor were pooled, mononu-
clear cell suspensions were isolated by Percoll (65%) separation
and human T cells (cT cells) were enriched with the Pan T cell
Isolation Kit II (Miltenyi Biotec, Bergisch Gladbach, Germany)
supplemented with a biotinylated rat anti-mouse CD45 antibody
(clone 30F-11, 5 mg/ml, ebiosciences, Frankfurt, Germany) to
remove mouse cells. Alternatively, human T cells (hT cells) were
enriched from human peripheral blood with the Pan T cell
Figure 1. HSPC engraftment in NSG-mice by intra-femoral or intra-hepatic injections. Adult or neonatal NSG mice were sublethally
irradiated and transplanted either intra-hepatically (neonatals: CB-HSPCs n = 8, 3 donors; BM-HSPCs n = 11 donors) or intra-femorally (adult: BM-HSPCs
n = 14, 11 donors) with CD34+ HSPCs. Mice were analyzed at .20 weeks after transplantation by flow cytometry. (A) The number of injected CD34+
HSPCs for each group is given. (B) Engraftment was determined by human CD45 expression. The absolute number of hCD45+ cells in BM and spleen
of reconstituted mice is shown. Indicated are values for significant differences between the groups. Bone marrow: CB i.h. vs. BM i.h., p = 0.003; CB i.h.
vs. BM i.f., p = 0.004; Spleen: CB i.h. vs. BM i.h., p = 0.04; CB i.h. vs. BM i.f., p,0.0001; ANOVA, Kruskal-Wallis). Each symbol represents an individual
animal. (C) The proportion of B cells and myeloid cells in BM and spleen is shown as percentage of human CD45+ cells. Each symbol represents an
individual animal. (D) left: The percentage of mice with T cells in spleen at .20 weeks after transplantation is given. right: The absolute number of
CD3+ T cells in the spleen of mice with T cells is shown. Due to the limited number of samples in two of the three groups no statistically analysis was
performed.
doi:10.1371/journal.pone.0097860.g001
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Isolation Kit II (Miltenyi Biotec, Bergisch Gladbach, Germany).
Human T cells isolated from peripheral blood or humanized mice
were labeled with CFDA-SE (ebioscience, Frankfurt, Germany) at
2 mM for 10 min at 37uC in PBS/1% FBS and washed twice.
CFSE-labeled T cells were cultured with irradiated cells (30 Gy) of
the non-T cell fraction from the enrichment of human peripheral
blood T cells or cT cells from humanized mice. Cells were plated
in RPMI 1640, 2 mM glutamine, 100 U/ml penicillin, 100 mg/
ml streptomycin, 10% heat-inactivated FCS, 55 mM b-mercapto-
ethanol (all life technologies, Darmstadt, Germany). Responder
cells were plated at a concentration of 26105 per well with or
without stimulator cells (2–46105/well) in round-bottom 96-well
tissue culture plates in a total volume of 200 ml at 37uC and 5%
CO2. After 5 or 6 days cells were harvested and stained with anti-
human CD3-PerCP-Cy5.5 and anti-human CD45-APC and the
proliferation of CD45+CD3+ cells was analyzed by flow cytometry.
Alternatively, BM-derived DCs from the BM of femura and
tibiae of NSG-HLA-A2/HHD mice were generated. Cells were
cultured in RPMI 1640 supplemented with 2 mM glutamine,
100 U/ml penicillin, 100 mg/ml streptomycin, 10% heat-inacti-
vated FCS and 1% v/v murine granulocyte–macrophage colony-
stimulating factor (GM-CSF, own production) as described
previously [12]. Cells were harvested at day 8 and stimulated
overnight with 1 mg/ml LPS (E.coli O127:B8, Sigma-Aldrich,
Taufkirchen, Germany). After washing cells for 3 times in PBS,
cells were used as stimulator cells at a concentration of 0.05–
36104 cells per well with 16105 murine CD8 T cells (C57BL/6)
or human peripheral blood CD8 T cells as responder cells.
Statistical Analysis
Statistical analysis was done using GraphPad Prism 6.0 software
(GraphPad Software, Inc., San Diego, USA). Differences in
medians between groups were analyzed by Student’s t-test, Mann-
Whitney-U or Kruskal-Wallis test where appropriate. Correlations
were evaluated using the Spearman rank correlation coefficient
method. A p-value of less than 0.05 and 0.001 were considered to
be statistically significant and highly significant, respectively.
Results
Diagnostic bone marrow aspirates were obtained from 77 non-
metastasized carcinoma patients diagnosed with non-metastasized
lung (n= 29), breast (n = 28), prostate (n = 14) or oesophageal
cancer (n = 6), and with a median age of 62 years (Table 1). The
aspirates were obtained from five different clinical sites during
primary tumor resection of the patients. To achieve long-term
reconstitution of NSG mice with human immune cells, an intra-
hepatic injection of CD34+ HSPC into newborn NSG mice is
currently considered to result in best engraftment [13]. As the
arrival of diagnostic bone marrow aspirates cannot be scheduled
and rarely matches with the availability of newborn mice, we
tested whether intra-femoral injections of BM-derived CD34+
HSPC into adult NSG mice gives a comparable reconstitution
Table 1. Patient data.
statistics sample volume [ml] BM-MNCs [6106] HSPC [6106] HSPCs per 106 BM-MNCs [6104] age [years]
BM (n=77) median 15.3 71 0.8 5.3 62
min-max 5–27 11.8–1090 0.01–110 0.06–47.9 30–83
cord-blood (n =31) median 60 275 1.1 1.6 –
min-max 30–100 73–1300 0.17–3.36 0.3–4.2 –
For human bone marrow aspirates of non-metastasized carcinoma patients and cord-blood samples, the median sample size, age and obtained number of BM-MNCs
and HSPCs are given. The distribution of the carcinoma type was as follows: lung 29/77, mammary 28/77, prostate 14/77 and oesophageal 6/77.
doi:10.1371/journal.pone.0097860.t001
Figure 2. Yield of CD34+ HSPCs isolated from cryoconserved and non-cryoconserved BM- MNCs. (A) BM mononuclear cells from BM-
aspirates were isolated by density centrifugation and frozen in liquid nitrogen. After maximally 6 months of storage cells were thawed and counted.
(B) CD34+ HSPCs were isolated from BM-MNCs at the day of arrival (immediate), the next day after overnight storage of BM-MNCs at 4uC or from
cryoconserved samples. The number of CD34+ cells per 10 million BM-MNCs is shown (p= 0.001 immediate vs. cryo and p= 0.0168 next day vs. cryo;
ANOVA Kruskal-Wallis).
doi:10.1371/journal.pone.0097860.g002
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with human immune cells as intra-hepatic injections of BM- or
cord-blood derived HSPCs into neonatal mice. An intra-femoral
injection is considered as an appropriate alternative route for the
transplantation of a limited number of human HSPCs [14].
Hence, we cryoconserved cord-blood (CB) or bone marrow
mononuclear cells (BM-MNCs), isolated HSPCs on the day of
transplantation and injected all mice with comparable numbers of
cells (Figure 1A). Depending on their age, neonatal and adult mice
of the intra-hepatic and intra-femoral groups were irradiated with
different doses of sublethal irradiation (1 vs. 3 Gy), which might
affect stromal cell numbers differently. We therefore compared the
reconstitution level between the groups by the absolute numbers
and not the percentage of human CD45 cells in BM and spleen
(Figure 1B).
The reconstitution with human CD45 cells in BM and spleen of
mice that had received cord-blood derived HSPCs was highest of
all groups, consistent with the known better immune reconstitution
obtained with HSPCs from neonatal than adult donors (Figure 1B)
[15–17]. In contrast, mice transplanted with BM-HSPCs intra-
hepatically or intra-femorally displayed fewer human leukocytes,
with no significant difference between both groups. Analyzing the
contribution of the myeloid and lymphoid lineage to the immune
reconstitution, we found that mice transplanted with BM-HSPCs
developed myeloid and B cells (Figure 1C), but only 20–40% of the
mice had detectable T cells in the spleen 20 weeks after
transplantation (Figure 1D). In contrast, all mice transplanted
with CB-HSPCs developed T cells and had higher numbers of T
cell. Due to the low number of transplanted mice that developed T
cells no definite conclusion can be drawn regarding the best
application route of cryopreserved BM-HSPCs (Fig. 1D).
In line with these data, we had observed that thawing of BM-
MNCs resulted in a median loss in the sample’s cellularity of 72%
(8%–85%, Figure 2A). Therefore, we examined the effect of
cryoconservation of BM-MNCs on the yield of CD34+ cells and
the qualitative and quantitative immune cell reconstitution. For
this, HSPCs were isolated either on the day of arrival or the next
morning after overnight storage of BM-MNCs at 4uC. These
samples were compared to samples of which BM-MNCs were
cryoconserved on the day of arrival and thawed shortly before
HSPC-isolation and transplantation.
A significantly lower yield (determined as the number of CD34+
cells per 10 million BM-MNCs) was obtained when HSPCs were
isolated from cryoconserved samples (immediate vs. cryo:
p = 0.001; next day vs. cryo: p = 0.017; Figure 2B). In contrast,
no significant difference (p = 0.27) could be detected in the yield of
HSPCs between samples processed on the day of arrival
(immediate) or after overnight storage at 4uC (next day)
(Figure 2B). Next, we transplanted intra-femorally HSPCs from
cryoconserved or non-cryoconserved BM samples (Figure 3A). We
used from all samples the maximal number of HSPCs as our
interest was to identify the most suitable protocol. This resulted in
injection of a higher median number of HSPCs from non-
cryoconserved samples (p = 0.005). For bone marrow and spleen
we found no significant difference (both p= 0.21) in the
reconstitution with hCD45+ cell for immediately isolated and
transplanted BM-HSPCs vs. samples injected on the next day after
overnight storage of BM-MNCs at 4uC (Figure S1). Therefore, we
combined these samples as non-cryoconserved group and com-
pared it to the group transplanted with cryoconserved cells.
We observed a significantly lower reconstitution with hCD45+
cells in BM and spleen, if HSPCs were isolated from cryocon-
served BM (BM: p= 0.03; Spleen: p = 0.0003, Mann-Whitney test;
Figure 3B). Comparing the development of the different hema-
topoietic cell lineages, we found that both groups developed
Figure 3. NSG mice engrafted with cryoconserved or non-
cryoconserved BM-HSPCs by intra-femoral injections. Adult NSG
mice were sublethally irradiated and transplanted with cryoconserved
(n = 14, 11 donors) or non-cryoconserved BM-HSPCs (n = 14, 13 donors).
At .20 weeks after transplantation mice were analyzed by flow
cytometry. (A) The number of injected CD34+ HSPCs for each group is
given. As the yield of CD34+ cells is higher from non-cryoconserved BM
samples, the respective group received significantly more HSPCs
(p = 0.0045, student‘s t-test). (B) Engraftment in BM and spleen was
determined by human CD45 expression. The absolute number of
hCD45+ cells in BM and spleen of the reconstituted mice is shown, each
symbol represents an individual animal. Indicated are values for
significant differences between the groups (BM: p = 0.03, Spleen
p=0.0003, Mann-Whitney test) (C) Representative flow cytometric
analysis of BM and spleen for CD19+ B cells, CD33+ myeloid cells and
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myeloid cells and B cells (Figure 3C). Consistent with previous
reports, the majority of B cells did not develop beyond the
immature/transitional B cell stage in BM and spleen [18]. In
spleen myeloid dendritic cells and plasmacytoid dendritic cells
were detected, with the latter showing upregulation of CD86 and
CD40 (Figure 3D). Interestingly, the percentage of mice with T
cell development in the spleen was clearly increased (83.3% vs.
21%), in the group with non-cryoconserved HSPCs and almost
reached the level obtained with intra-hepatic transplantations of
cord-blood derived HSPCs (Figure 3E). Yet, the splenic T cell
number in mice reconstituted with non-cryoconserved BM-HSPCs
was significantly lower than in CB-HSPC transplanted mice (p,
0.01; Mann-Whitney test). Nevertheless, we could observe T cell
development in the thymus more than 20 weeks after transplan-
tation of BM-HSPCs.
In the thymus epithelial cells mediate positive selection of
developing T cells. As NSG mice do not express HLA-molecules
on thymic epithelial cells, human T cells developing in these mice
lack the ability to recognize antigens and function in an HLA-
restricted manner [6,19]. In NSG-HLA-A2/HHD mice [19] the
HLA-A2 allele is ubiquitously expressed, which prompted us to
test whether the inferior T cell development in BM-HSPC
reconstituted NSG-mice could be improved in HLA-I transgenic
NSG-mice.
Intra-femoral transplantations in comparison to intra-venous
injections are technically difficult and harbor the risk of lethal
infections for the recipient mice. Furthermore, the most commonly
used injection routes for HSPC into neonatal NSG mice (i.h., i.v.,
intra-cardiac) all introduce the injected cells directly into the
circulation and no difference in engraftment was observed [13].
We therefore injected the BM-HSPCs intra-venously into NSG-
HLA-A2/HHD mice. Analysis of the peripheral blood at 7, 10, 14
and 19 weeks after HSPC-transplantation revealed that the
percentage of hCD45 cells decreases over time, but stabilizes
around week 14 (Fig. 4A) suggesting that at around this time point
immune cell reconstitution starts to depend on HSC with long-
term reconstitution potential. The percentage of T cells in blood
started to increase after week 14 of HSPC-transplantation.
As reported for CB-HSPCs [19], NSG-HLA-A2/HHD mice
did not show a significant difference in the overall immune cell
reconstitution in BM and spleen as compared to NSG mice
(Fig. 4B). Interestingly, even though we transplanted NSG-HLA-
A2/HHD mice with cryoconserved HSPCs, 82% (19/23) of the
mice showed T cell development 19–20 weeks after transplanta-
tion. However, the absolute number of CD3 cells was still lower
than that of neonatal NSG mice transplanted with CB-HSPCs and
no significant difference in the number of CD3, CD4 (not shown)
or CD8 T cells (not shown) in the spleen of NSG-HLA-A2/HHD
and NSG-mice was observed (Figure 4C).
Although we could not observe any superiority of NSG-HLA-
A2/HHD over NSG-mice with regard to overall engraftment and
T cell development, we further explored this mouse strain, as these
mice were recently shown to enable HLA-I restricted T cell
responses after transplantation of human CB-HSPC [19] and
should enable the investigation of human CD8 T cell responses
against human, autologous cancers of HLA-A2+ patients. As a first
glimpse into T cell and DC function, we investigated their ability
to respond and activate. CD8 T cells in the spleen of NSG-HLA-
A2/HHD mice displayed a similar naive (CD45RA+CD27+)
phenotype as CD8 T cells from human peripheral blood, whereas
the majority of CD4 T cells showed signs of antigen-experience
(CD45RA-CD27+/2, Figure 4D). To analyze whether functional
and self-tolerant, human T cells had developed from BM-HSPCs,
we subjected these T cells to an in vitro mixed lymphocyte reaction
using allogeneic and autologous stimulator cells (Figure 4E). To
that end, we isolated human T cells from spleen and bone marrow
of mice humanized with BM-HSPCs from four different donors or
from mice transplanted with CB-HSPCs and referred to these cells
as chimeric T cells (cT cells). The cT cells were stimulated with
human T cell-depleted and irradiated mononuclear cells (hAPC)
from peripheral blood of a healthy HLA-A2 negative volunteer. As
control, hT cells from the same (auto) or different (allo) donor were
isolated and stimulated with hAPC. To test for self-tolerance, cT
cells isolated from cord-blood or BM-HSPC reconstituted mice
were cultured with autologous cAPC isolated from the same
humanized mouse, whereas hT cells were stimulated with
autologous hAPC. On day 5 of the mixed lymphocyte reaction,
proliferation of cT cells from both, CB- and BM-HSPC
transplanted mice could be detected when incubated with
allogeneic hAPC. The percentage of alloreactive cT cells from
BM-HSPC reconstituted mice was similar to cT cells from CB-
HSPCs transplanted mice. When the number of stimulator cells
(hAPC) was doubled and proliferation analyzed on day 6, $90%
human T cells from BM-HSPC transplanted mice proliferated.
Importantly and identical to hT cells stimulated with autologous
hAPC, cT cells from BM- or CB-HSPC transplanted mice were
self-tolerant and did not proliferate on autologous cAPC (auto,
d5+ d6). These cAPC were functional stimulator cells as they could
induce proliferation of allogeneic hT cells in a dose-dependent
manner (Figure S3A). Theoretically, also murine HLA-A2
expressing APCs could have activated hT cells in this assay.
Therefore, we compared the ability of in vitro generated BM-
derived, LPS-stimulated and HLA-A2 expressing murine DCs
from non-reconstituted NSG-HLA-A2/HHD mice to activate
human allogeneic CD8 T cells from a HLA-A2 negative donor or
murine C57BL/6-derived CD8 T cells in an in vitro mixed-
lymphocyte reaction (Figure S3B). Whereas NSG-HLA-A2/HHD
BM-DCs could induce proliferation in up to 37% of the murine
CD8 T cells, only maximally 5% of the human CD8 T cells were
dividing. These findings suggest that the activation of hT cells by
cAPCs can be mainly attributed to human antigen-presenting cells
reconstituted from transplanted BM-HSPCs.
These experiments assessed the influence of several factors
(cryoconservation, HLA-A2 expression, age of recipient mice at
transplantation, method of cell injection) on the immune cell
reconstitution and addressed the immune system’s ability to mount
a robust immune response (i.e. an allograft response). We then
sought to determine the number of BM-HSPCs required to
achieve CB-equivalent reconstitution. Finally, we asked whether
this number of HSPCs could be obtained from a single diagnostic
bone marrow to reconstitute several mice.
We used the group of NSG mice transplanted with non-
cryoconserved BM-HSPCs for this analysis. We defined the CB-
equivalent reconstitution as the number of human leukocytes in
spleen and bone marrow that was obtained with the lowest
CD3+ or CD3+CD4+/CD8+ T cells. B cell developmental stages in BM and
spleen are shown for CD24+CD38high/low cells. In BM pro/pre-B cells
were defined as CD10+ IgM-, immature B cells as CD10+IgM+. In spleen
mainly transitional (IgD+IgM+) B cells were detected. (D) Representative
flow cytometric analysis of the spleen for plasmacytoid and myeloid
dendritic cellls (pDC: Lin-CD123+CD11c-; mDC: Lin-CD1232CD11c+) and
their expression of costimulatory molecules (CD40, CD86) (E) Repre-
sentative flow cytometric analysis of CD3+ T cells in the thymus and
their expression of CD4 and CD8 at .20 weeks after transplantation.
The percentage of mice with CD3+ T cells and their absolute number in
spleen at .20 weeks after transplantation is given (CB vs. non-cryo BM:
p,0.01, Mann-Whitney test).
doi:10.1371/journal.pone.0097860.g003
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Figure 4. Reconstitution of a functional, HLA-restricted and self-tolerant T cell repertoire. Adult sublethally irradiated NSG-HLA-A2/HHD
mice were transplanted intra-venously with cryoconserved CD34+ HSPCs (n = 23 mice, 13 donors). At different time points after transplantation mice
were analyzed by flow cytometry and final analysis of organs was performed at 18–20 weeks after reconstitution. (A) Flow cytometric analysis of
peripheral blood of reconstituted mice (n = 12 mice) at 7–19 weeks after BM-HSPC transplantation. Shown is the % of hCD45+, hCD45+CD19+ (B cells),
hCD45+CD33+ (myeloid cells) or hCD45+CD3+ (T cells) cells (median with interquartile range). (B) Engraftment in BM and spleen was determined by
human CD45 expression. The absolute number of hCD45+ cells in BM and spleen of the reconstituted mice is shown and compared to NSG-mice
reconstituted with non-cryoconserved BM-HSPCs (see Fig. 3B). Each symbol represents an individual animal. Indicated are values for significant
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number of transplanted CB-HSPCs in our study that gives a
reconstitution level matching with published data [20]: the
transplantation of 4.86104 CB-HSPCs resulted in 1.76106 and
66106 human leukocytes in spleen and bone marrow, respectively.
In BM-HSPC humanized mice, a highly significant correlation
was found between the number of transplanted HSPCs and
human leukocytes in bone marrow and spleen of humanized mice
(BM: r = 0.85, p= 0.0002; Spleen: r = 0.67, p= 0.001; Spearman).
Linear regression analysis (Figure 5A) showed that about 1.7–
2.16105 CD34+ cells, i.e. approximately 5-fold more BM- than
CB-HSPCs, are needed to reach CB-equivalent reconstitution.
Usually, less than 10 animals can be reconstituted with one
cord-blood sample [21], whereas from bone marrow aspirates of
healthy volunteers and type I diabetes patients 1–2 and 7 recipient
mice were generated, respectively [16,22]. We therefore calculated
the number of BM-MNCs required for the isolation of 1.266106
HSPCs, a number sufficient for the generation of six mice with
CB-equivalent reconstitution level as stated above. This number of
mice would enable meaningful experimental comparisons from
one patient. The number of isolated HSPCs from non-cryocon-
served samples correlated with the number of patient-isolated BM-
MNCs (r = 0.66; p,0.0001; Spearman) and linear regression
analysis revealed that 16108 BM-MNCs (Figure 5B) are required
for the isolation of 1.266106 HSPCs.
For assessment of minimal systemic cancer spread to bone
marrow, we had obtained diagnostic bone marrow aspirates of 77
M0-stage patients. We received a median volume of 15.3 ml and
could isolate in median 7.16107 BM-MNCs (Table 1). From these
differences between the groups (BM: p = 0.64; Spleen: p = 0.19, Mann-Whitney test). (C) In comparison to CB- (n = 8 mice) and BM-HSPC (n = 10 mice)
transplanted NSG mice (i.h. and i.f. respectively), the absolute number of splenic CD3+ T cells is given for NSG-HLA-A2/HHD mice (n = 19 mice). Each
symbol represents an individual animal. Indicated are values for significant differences between the groups (CB vs BM-NSG: p = 0.009; CB vs BM-HHD:
p = 0.0027, Kruskal-Wallis test). (D) Representative flow cytometric analysis of splenic CD3+CD4+ and CD3+CD8+ T cells and their respective expression
of CD27 and CD45RA. In addition, CD27 and CD45RA expression of peripheral blood T cells of a healthy volunteer is shown. (E) Mixed lymphocyte
reaction of human T cells isolated from NSG-HLA-A2/HHD mice ( = chimeric T cells, cT) transplanted with CB- (n = 1 donor, 2 mice) or BM-HSPCs (n = 4
donors, each 2–3 mice). CFSE-labeled cT cells were stimulated with human T cell-depleted and irradiated peripheral blood mononuclear cells (hAPC,
d5:26105 cells/well; d6:26105 cells/well). As control, human T cells from peripheral blood of the same (auto, n = 2) or different (alllo, n = 2) HLA-A2
negative donor were isolated. Self-tolerance was tested incubating cT cells or hT cells on autologous T cell depleted, irradiated cAPC or hAPC from
the same humanized mouse or human volunteer. Proliferation of T cells was measured after 5 or 6 days based on the gradual loss of the CFSE-label.
doi:10.1371/journal.pone.0097860.g004
Figure 5. Determination of the minimal number of BM-HSPCs, BM-MNCs and volume of BM-aspirate required for the reconstitution
of NSG mice. Six-to eight week-old sublethally irradiated NSG mice were transplanted intra-femorally with non-cryoconserved CD34+ HSPCs (n = 14,
11 donors). (A) At .20 weeks after transplantation mice were analyzed by flow cytometry and engraftment in BM and spleen was determined by
human CD45 expression and plotted vs. the number of injected HSPCs. The number of BM-HSPCs is calculated, which is required to achieve
reconstitution in BM and spleen comparable to the lowest number of transplanted CB-HSPCs (4.86104 injected CD34+ HSPCs) that gives a
reconstitution level matching with published data (BM: 66106 hCD45+; spleen 1.76106 hCD45+). Linear regression analysis revealed that at least 1.7–
2.16105 BM-HSPCs are needed. (B) The number of BM-MNCs at sample receipt is plotted vs. the number of isolated HSPCs. The number of BM-MNCs
(108) is calculated that is required to isolate HSPCs sufficient for the reconstitution of six mice from one BM sample, given that each mouse receives
2.16105 HSPCs. (C) The number of CD34+ HSPCs per 10 million BM-MNCs is plotted vs. the age of carcinoma (n = 77) or control-patients (n = 7). No
correlation is observed. (D) Percentage of samples and the volume of samples at receipt, which contained $108 BM-MNCs allowing the isolation of
HSPCs sufficient for the transplantation of six mice.
doi:10.1371/journal.pone.0097860.g005
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77 aspirates, 28 samples (36%) had $108 BM-MNCs and from 31
samples (40%) $106 HSPCs could be isolated. We did not observe
a correlation between the number of isolated CD34+ cells and
patient age (Figure 5C) or carcinoma type (Figure S2). Also, the
frequency of CD34+ HSPCs in carcinoma patients was similar to
non-carcinoma patients (Figure 5C). Interestingly, the number of
BM-MNCs allowed a better estimation whether $106 HSPCs
would be obtained than the volume of the arriving bone marrow
aspirate: the chance to isolate 106 HSPCs cells differed marginally
between samples with 5–10 ml or 10–20 ml volume, i.e. a 5 ml
aspirate could contain a similar number of isolated HSPCs than a
20 ml sample (Figure 5D). Only when we had received more than
20 ml bone marrow we could always isolate the required number
of HSPCs.
Discussion
Here we show that an immune system can be generated in
immunodeficient mice using CD34+ HSPCs from bone marrow
aspirates of non-metastasized carcinoma patients. Bone marrow
sampling is performed to assess minimal cancer spread at the time
of primary surgery and the prognostic value of DCC detection in
bone marrow is currently considered to be better than that of
circulating tumor cells [23,24]. Therefore, bone marrow is, in
addition to the primary tumor, a source of highly relevant cancer
cells whose interaction with immune cells is unstudied so far. This
limitation could be overcome if autologous cancer and immune
cells were explored in double-humanized mouse models. The
specific challenge of such experiments lies in the complex
interdependence of sample and recipient mouse availability with
experimental needs and conditions. Here, we analyzed the
requirements for immune humanization such that it can be
combined with autologous xenografts from bone marrow, blood,
or primary tumor derived cancer cells in the future.
We used cord blood HSPCs as gold standard and compared
sample preparation methods and routes of HSPC application. We
observed that cryoconservation of BM-MNCs negatively affects
the yield of isolated CD34+ HSPCs and reconstitution with
hCD45+ in BM and spleen, which was particularly evident for
peripheral T cells. This is in line with a recent study showing that
cryoconservation of cord-blood cells not only decreases the
percentage of peripheral blood hCD45+ cells, but also the
proliferation of T cells in vitro in response to anti-CD3 stimulation
[25]. In contrast, overnight storage of BM-MNCs with isolation
and transplantation of HSPCs on the next day, neither affects the
HSPC-yield, nor the in vivo immune cell reconstitution. Given the
significant drop of total cell recovery upon thawing of BM-MNCs,
it is most likely that the number of long-term hematopoietic
repopulating cells is also greatly diminished. We found that five-
times more BM-HSPCs need to be injected to achieve reconsti-
tution indices comparable to CB-HSPCs. This is consistent with
the previously discussed reduced repopulating and lymphopoietic
activity of BM-HSPCs compared to CB-HSPCs [15,16,26].
Therefore, reduced stem cell numbers in cryoconserved samples
will have greater impact on the reconstitution with BM-samples
than CB-samples.
The sample receipt of diagnostic bone marrow rarely matches
the availability of newborn mice. This fact and the negative impact
of freeze-thaw cycles necessitate transplanting HSPCs into adult
mice. We found that the qualitative and quantitative immune cell
reconstitution does not differ significantly between intra-femoral
injections into adult and intra-hepatic injections into neonatal
mice of BM-HSPCs. In addition, we did not observe disadvantages
from intra-venous injections for CB-HSPCs when compared to
intra-femoral and intra-hepatic injections (unpublished data). Also,
the development of functional T cells in NSG-HLA-A2/HHD
mice after i.v. injection shown here suggests that this is not
different for BM-HSPCs. Therefore, although we did not directly
compare intra-femoral and intra-hepatic with intra-venous injec-
tions, we expect i.v. injections to result in comparable engraftment.
As i.v. injections are easy and fast to perform and carry minimal
risk of infection for the severely immunocompromised recipients,
we now prefer intra-venous injections into adult mice for the
transplantation of BM-HSPCs.
We deemed particularly interesting to assess whether the human
antigen-presenting cells and T cells that are reconstituted from
BM-HSPCs can mold an allogeneic T cell response. To this end
we tested and confirmed both, self-tolerance and reactivity of T
cells developing in NSG-HLA-A2/HHD mice, and the potential
of cAPCs to prime T cell responses. Of interest, the proportion of
mice with long-term T cell reconstitution in spleen was higher in
NSG-HLA-A2/HHD than in NSG mice, although we used
cryoconserved BM-HSPCs for this experiment. Therefore, it is
very likely that T cell development in NSG-HLA-A2/HHD mice
may be improved by using freshly isolated BM-HSPCs or
transplanting into younger recipient-mice (3–4 weeks instead of
6–8 weeks) before thymic involution [13]. Additional enhance-
ment may be achieved by supplementing homeostatic cytokines
such as hIL-7 [27], as murine IL-7 has only low activity on the
human receptors [28]. A more difficult way employs additional
transplantation of HLA-matched fetal thymic grafts [22], as this
requires the availability of a ready-to-use bank of fetal-thymic
tissue, HLA-matched for at least one allele of the cancer patient.
Finally, we retrospectively analyzed how diagnostic bone
marrow samples should be selected to set up double-humanized
mice, consisting of autologous immune and cancer cells. We found
that about 2.16105 HSPCs per animal are needed to achieve a
CB-equivalent reconstitution. Since six times this number can be
obtained from a BM volume of 10–20 ml (the volume recom-
mended by the consensus protocol for DCC detection [11]), in
40% of cases about six mice can be generated from one sample.
This number is in the range of previous experiments using adult
bone marrow [22]. Slightly higher aspirate-volumes would enable
reconstitution of more animals and increase the proportion of
suitable samples. Alternatively, recently developed protocols for
the in vitro expansion of long-term repopulating cord-blood
hematopoietic stem cells [29,30] might prove helpful for BM
hematopoietic stem cells as well. Taken together, we provide an
important framework for the use of diagnostic BM-aspirates from
carcinoma patients as adult HSPC-source. Future experiments
need to assess whether double-humanized NSG-HLA-A2/HHD
mice from BM-HSPCs and autologous cancer cells of HLA-A2+
patients will generate HLA-A2 restricted T cell responses against
tumor and non-tumor antigens in vivo. If so, our model will enable
novel ways to investigate tumor immunology of early systemic
cancer.
Supporting Information
Figure S1 NSG mice engrafted with BM-HSPCs isolated
at the day of arrival or the next day. Adult NSG mice were
sublethally irradiated and transplanted with BM-HSPCs that were
isolated and transplanted on the day of arrival (immediate, n = 7, 7
donors) or the next day (next day, n= 7, 6 donors). At .20 weeks
after transplantation mice were analyzed by flow cytometry.
Engraftment in BM and spleen was determined by human CD45
expression. The absolute number of hCD45+ cells in BM and
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spleen of the reconstituted mice is shown, each symbol represents
an individual animal.
(TIF)
Figure S2 The HSPC-yield is independent of the carci-
noma type. No correlation between the number of CD34+
HSPCs per 10 million BM-MNCs and the respective type of
carcinoma (mammary carcinoma (n= 28), lung cancer (n = 29)
and prostate carcinoma (n= 14)) is observed.
(TIF)
Figure S3 The T cell stimulatory capacity of antigen-
presenting cells in reconstituted mice. (A) Different
numbers of allogeneic cAPC from BM-HSPC reconstituted mice
were used to stimulate CFSE-labeled hT cells and proliferation
was measured after 5 or 6 days based on the gradual loss of the
CFSE-label. (B) Different numbers of mature BM-derived and
LPS-stimulated dendritic cells (BM-DCs) from non-reconstituted
NSG-HLA-A2/HHD mice were used as stimulator cells for
murine CD8 T cells from C57BL/6 mice or human peripheral
blood CD8 T cells from an HLA-A2 negative healthy donor. All T
cells were labeled with CFDA-SE and proliferation was measured
after 5 days based on the gradual loss of the CFSE-label.
(TIF)
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